• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新型三特异性B7-H3xCD16xTIGIT 2+1共轻链自然杀伤细胞衔接器强力诱导细胞凋亡

Potent Apoptosis Induction by a Novel Trispecific B7-H3xCD16xTIGIT 2+1 Common Light Chain Natural Killer Cell Engager.

作者信息

Ulitzka Michael, Harwardt Julia, Lipinski Britta, Tran Hue, Hock Björn, Kolmar Harald

机构信息

Institute for Organic Chemistry and Biochemistry, Technical University of Darmstadt, Peter-Grünberg-Str. 4, 64287 Darmstadt, Germany.

Centre of Synthetic Biology, Technical University of Darmstadt, 64283 Darmstadt, Germany.

出版信息

Molecules. 2024 Mar 4;29(5):1140. doi: 10.3390/molecules29051140.

DOI:10.3390/molecules29051140
PMID:38474651
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10935230/
Abstract

Valued for their ability to rapidly kill multiple tumor cells in succession as well as their favorable safety profile, NK cells are of increasing interest in the field of immunotherapy. As their cytotoxic activity is controlled by a complex network of activating and inhibiting receptors, they offer a wide range of possible antigens to modulate their function by antibodies. In this work, we utilized our established common light chain (cLC)-based yeast surface display (YSD) screening procedure to isolate novel B7-H3 and TIGIT binding monoclonal antibodies. The chicken-derived antibodies showed single- to low-double-digit nanomolar affinities and were combined with a previously published CD16-binding Fab in a 2+1 format to generate a potent NK engaging molecule. In a straightforward, easily adjustable apoptosis assay, the construct B7-H3xCD16xTIGIT showed potent apoptosis induction in cancer cells. These results showcase the potential of the TIGIT NK checkpoint in combination with activating receptors to achieve increased cytotoxic activity.

摘要

自然杀伤(NK)细胞因其能够连续快速杀死多个肿瘤细胞以及良好的安全性而受到重视,在免疫治疗领域越来越受到关注。由于其细胞毒性活性受激活和抑制受体的复杂网络控制,它们提供了广泛的可能抗原,可通过抗体调节其功能。在这项工作中,我们利用已建立的基于共同轻链(cLC)的酵母表面展示(YSD)筛选程序,分离新型B7-H3和TIGIT结合单克隆抗体。鸡源抗体显示出单位数到低双位数纳摩尔的亲和力,并与先前发表的以2+1形式结合CD16的Fab片段组合,以产生一种有效的NK细胞接合分子。在一个简单、易于调整的凋亡试验中,构建体B7-H3xCD16xTIGIT在癌细胞中显示出强大的凋亡诱导作用。这些结果展示了TIGIT NK细胞检查点与激活受体结合以实现增强细胞毒性活性的潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c142/10935230/b57fc6f806b1/molecules-29-01140-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c142/10935230/0b5055b628e1/molecules-29-01140-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c142/10935230/9ca50deecd06/molecules-29-01140-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c142/10935230/7853807dbe39/molecules-29-01140-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c142/10935230/29ba56dafd73/molecules-29-01140-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c142/10935230/6bab7af7ab42/molecules-29-01140-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c142/10935230/2e7278008cda/molecules-29-01140-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c142/10935230/b57fc6f806b1/molecules-29-01140-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c142/10935230/0b5055b628e1/molecules-29-01140-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c142/10935230/9ca50deecd06/molecules-29-01140-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c142/10935230/7853807dbe39/molecules-29-01140-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c142/10935230/29ba56dafd73/molecules-29-01140-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c142/10935230/6bab7af7ab42/molecules-29-01140-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c142/10935230/2e7278008cda/molecules-29-01140-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c142/10935230/b57fc6f806b1/molecules-29-01140-g007.jpg

相似文献

1
Potent Apoptosis Induction by a Novel Trispecific B7-H3xCD16xTIGIT 2+1 Common Light Chain Natural Killer Cell Engager.新型三特异性B7-H3xCD16xTIGIT 2+1共轻链自然杀伤细胞衔接器强力诱导细胞凋亡
Molecules. 2024 Mar 4;29(5):1140. doi: 10.3390/molecules29051140.
2
Design of a Trispecific Checkpoint Inhibitor and Natural Killer Cell Engager Based on a 2 + 1 Common Light Chain Antibody Architecture.基于 2+1 共用轻链抗体结构的三特异性检查点抑制剂和自然杀伤细胞衔接子的设计。
Front Immunol. 2021 May 10;12:669496. doi: 10.3389/fimmu.2021.669496. eCollection 2021.
3
Generation of a symmetrical trispecific NK cell engager based on a two-in-one antibody.基于双功能抗体的对称三特异性自然杀伤细胞衔接子的构建。
Front Immunol. 2023 Apr 4;14:1170042. doi: 10.3389/fimmu.2023.1170042. eCollection 2023.
4
Bispecific killer cell engager with high affinity and specificity toward CD16a on NK cells for cancer immunotherapy.双特异性杀伤细胞接合器,对 NK 细胞表面的 CD16a 具有高亲和力和特异性,用于癌症免疫治疗。
Front Immunol. 2023 Jan 6;13:1039969. doi: 10.3389/fimmu.2022.1039969. eCollection 2022.
5
Affinity Maturation of B7-H6 Translates into Enhanced NK Cell-Mediated Tumor Cell Lysis and Improved Proinflammatory Cytokine Release of Bispecific Immunoligands via NKp30 Engagement.B7-H6的亲和力成熟通过NKp30的参与转化为增强的自然杀伤细胞介导的肿瘤细胞裂解,并改善双特异性免疫配体的促炎细胞因子释放。
J Immunol. 2021 Jan 1;206(1):225-236. doi: 10.4049/jimmunol.2001004. Epub 2020 Dec 2.
6
When three is not a crowd: trispecific antibodies for enhanced cancer immunotherapy.当三不是一群人时:用于增强癌症免疫疗法的三特异性抗体。
Theranostics. 2023 Jan 22;13(3):1028-1041. doi: 10.7150/thno.81494. eCollection 2023.
7
Engineering of Anti-CD133 Trispecific Molecule Capable of Inducing NK Expansion and Driving Antibody-Dependent Cell-Mediated Cytotoxicity.工程化抗 CD133 三特异性分子,能够诱导 NK 细胞扩增并驱动抗体依赖的细胞介导的细胞毒性。
Cancer Res Treat. 2017 Oct;49(4):1140-1152. doi: 10.4143/crt.2016.491. Epub 2017 Feb 20.
8
A Transformable Supramolecular Bispecific Cell Engager for Augmenting Natural Killer and T Cell-Based Cancer Immunotherapy.一种可变形的超分子双特异性细胞衔接子,用于增强自然杀伤细胞和 T 细胞为基础的癌症免疫疗法。
Adv Mater. 2024 Jan;36(3):e2306736. doi: 10.1002/adma.202306736. Epub 2023 Dec 1.
9
Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies.双特异性和三特异性免疫细胞衔接器在血液系统恶性肿瘤免疫治疗中的应用。
J Hematol Oncol. 2023 Jul 27;16(1):83. doi: 10.1186/s13045-023-01482-w.
10
Trispecific killer engager 161519 enhances natural killer cell function and provides anti-tumor activity against CD19-positive cancers.三特异性杀手结合物 161519 增强了自然杀伤细胞的功能,并针对 CD19 阳性癌症提供了抗肿瘤活性。
Cancer Biol Med. 2020 Nov 15;17(4):1026-1038. doi: 10.20892/j.issn.2095-3941.2020.0399. Epub 2020 Dec 15.

引用本文的文献

1
Natural Killer Cell Immune Checkpoints and Their Therapeutic Targeting in Cancer Treatment.自然杀伤细胞免疫检查点及其在癌症治疗中的靶向治疗
Research (Wash D C). 2025 Jun 3;8:0723. doi: 10.34133/research.0723. eCollection 2025.
2
Tumor-specific cytosol-penetrating antibodies for antigen- and TME-dependent intracellular cargo delivery.用于抗原和肿瘤微环境依赖性细胞内货物递送的肿瘤特异性胞质穿透抗体。
Mol Ther Oncol. 2025 Jan 2;33(1):200931. doi: 10.1016/j.omton.2024.200931. eCollection 2025 Mar 20.

本文引用的文献

1
Natural killer cell therapies.自然杀伤细胞疗法。
Nature. 2024 Feb;626(8000):727-736. doi: 10.1038/s41586-023-06945-1. Epub 2024 Feb 21.
2
Fc-competent multispecific PDL-1/TIGIT/LAG-3 antibodies potentiate superior anti-tumor T cell response.Fc 功能完整的多特异性 PDL-1/TIGIT/LAG-3 抗体增强抗肿瘤 T 细胞反应。
Sci Rep. 2023 Jun 18;13(1):9865. doi: 10.1038/s41598-023-36942-3.
3
Anti-TIGIT therapies for solid tumors: a systematic review.抗 TIGIT 疗法治疗实体瘤:系统评价。
ESMO Open. 2023 Apr;8(2):101184. doi: 10.1016/j.esmoop.2023.101184. Epub 2023 Mar 16.
4
When three is not a crowd: trispecific antibodies for enhanced cancer immunotherapy.当三不是一群人时:用于增强癌症免疫疗法的三特异性抗体。
Theranostics. 2023 Jan 22;13(3):1028-1041. doi: 10.7150/thno.81494. eCollection 2023.
5
Bispecific killer cell engager with high affinity and specificity toward CD16a on NK cells for cancer immunotherapy.双特异性杀伤细胞接合器,对 NK 细胞表面的 CD16a 具有高亲和力和特异性,用于癌症免疫治疗。
Front Immunol. 2023 Jan 6;13:1039969. doi: 10.3389/fimmu.2022.1039969. eCollection 2022.
6
Control of acute myeloid leukemia by a trifunctional NKp46-CD16a-NK cell engager targeting CD123.三功能 NKp46-CD16a-NK 细胞接合器通过靶向 CD123 控制急性髓细胞白血病。
Nat Biotechnol. 2023 Sep;41(9):1296-1306. doi: 10.1038/s41587-022-01626-2. Epub 2023 Jan 12.
7
Antitumor immunity induced by antibody-based natural killer cell engager therapeutics armed with not-alpha IL-2 variant.基于抗体的自然杀伤细胞衔接器治疗药物武装非-α IL-2 变体诱导的抗肿瘤免疫。
Cell Rep Med. 2022 Oct 18;3(10):100783. doi: 10.1016/j.xcrm.2022.100783.
8
To kill a cancer: Targeting the immune inhibitory checkpoint molecule, B7-H3.攻克癌症:靶向免疫抑制检查点分子B7-H3
Biochim Biophys Acta Rev Cancer. 2022 Sep;1877(5):188783. doi: 10.1016/j.bbcan.2022.188783. Epub 2022 Aug 24.
9
From CD16a Biology to Antibody-Dependent Cell-Mediated Cytotoxicity Improvement.从CD16a生物学特性到抗体依赖的细胞介导的细胞毒性改善
Front Immunol. 2022 Jun 3;13:913215. doi: 10.3389/fimmu.2022.913215. eCollection 2022.
10
All About (NK Cell-Mediated) Death in Two Acts and an Unexpected Encore: Initiation, Execution and Activation of Adaptive Immunity.自然杀伤细胞介导的死亡全剧分两幕及意外加演:适应性免疫的启动、执行与激活
Front Immunol. 2022 May 16;13:896228. doi: 10.3389/fimmu.2022.896228. eCollection 2022.